PL3307289T3 - Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt) - Google Patents

Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)

Info

Publication number
PL3307289T3
PL3307289T3 PL16732111T PL16732111T PL3307289T3 PL 3307289 T3 PL3307289 T3 PL 3307289T3 PL 16732111 T PL16732111 T PL 16732111T PL 16732111 T PL16732111 T PL 16732111T PL 3307289 T3 PL3307289 T3 PL 3307289T3
Authority
PL
Poland
Prior art keywords
mrt
compositions
manufacture
methods
restoration therapy
Prior art date
Application number
PL16732111T
Other languages
English (en)
Inventor
Lee A. Jones
Courtney R. JONES
Beth Anne-Szkudlarek Brown
Joshua ERICKSON
Original Assignee
Rebiotix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rebiotix, Inc. filed Critical Rebiotix, Inc.
Publication of PL3307289T3 publication Critical patent/PL3307289T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16732111T 2015-06-09 2016-06-09 Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt) PL3307289T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562173182P 2015-06-09 2015-06-09
US201562247825P 2015-10-29 2015-10-29
PCT/US2016/036714 WO2016201114A1 (en) 2015-06-09 2016-06-09 Microbiota restoration therapy (mrt) compositions and methods of manufacture
EP16732111.6A EP3307289B1 (en) 2015-06-09 2016-06-09 Methods of manufacture of microbiota restoration therapy (mrt) compositions

Publications (1)

Publication Number Publication Date
PL3307289T3 true PL3307289T3 (pl) 2022-01-17

Family

ID=56203991

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16732111T PL3307289T3 (pl) 2015-06-09 2016-06-09 Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)

Country Status (13)

Country Link
US (2) US10226431B2 (pl)
EP (2) EP3307289B1 (pl)
JP (2) JP6616431B2 (pl)
KR (3) KR102175829B1 (pl)
CN (1) CN107921072A (pl)
AU (4) AU2016274757B2 (pl)
BR (1) BR112017026586B1 (pl)
CA (1) CA2986915C (pl)
ES (1) ES2889902T3 (pl)
HK (1) HK1254281A1 (pl)
IL (2) IL281424B2 (pl)
PL (1) PL3307289T3 (pl)
WO (1) WO2016201114A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
US12050161B2 (en) 2015-04-24 2024-07-30 Maat Pharma Microorganism sampling method, microorganism sampling device and sampling kit comprising such a sampling device
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
US10092601B2 (en) * 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
EP3388069B1 (en) 2017-04-12 2019-05-01 ETH Zurich Consortia of living bacteria useful for treatment of microbiome dysbiosis
US20220125042A1 (en) * 2017-05-17 2022-04-28 Universidade Nova De Lisboa Cryoprotectant and/or cryopreservant composition, methods and uses thereof
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
EP3695017A1 (en) 2017-10-13 2020-08-19 Rebiotix, Inc. Microbiome health index
EP3485879A1 (en) 2017-11-17 2019-05-22 Maat Pharma Pharmaceutical oral formulation comrpsing bacteria
WO2019213595A1 (en) 2018-05-04 2019-11-07 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
EP3806874A1 (en) * 2018-06-14 2021-04-21 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US20210283197A1 (en) * 2018-07-17 2021-09-16 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
CN109679877A (zh) * 2019-01-17 2019-04-26 广州承葛生物科技有限公司 一种高活性粪菌胶囊的制备方法
WO2021076999A1 (en) 2019-10-18 2021-04-22 Hubble Bioscience Inc. Fecal-derived sterile postbiotic composition and method therefor
JP2023509245A (ja) 2019-12-30 2023-03-08 奇▲輝▼生物科技（▲揚▼州）有限公司 腸管内容物分離回収装置、方法及び抽出物
BR112022024128A2 (pt) 2020-06-01 2022-12-27 Ferring Bv Composição de microbiota vaginal, e, método para tratar uma infecção
CN116322371A (zh) 2020-08-14 2023-06-23 普罗莱克塔生物科学公司 与细菌疗法一起使用的人乳寡糖组合物
WO2022051610A1 (en) 2020-09-04 2022-03-10 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
CN112089736B (zh) * 2020-09-22 2022-07-15 苏州普瑞森生物科技有限公司 一种全菌胶囊及其制备方法和应用
CN112826836A (zh) * 2021-01-08 2021-05-25 深圳未知君生物科技有限公司 一种粪菌口服制剂及其制备方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL257275A (pl) 1959-10-26
DE3887353T2 (de) 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
WO1989005659A1 (en) 1987-12-24 1989-06-29 Borody Thomas J Orthostatic lavage solutions
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
CA1337265C (en) 1988-08-04 1995-10-10 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
DE69133348T3 (de) 1990-10-22 2011-05-12 Centre for Digestive Diseases Pty, Ltd. Behandlung von nicht-entzündlichen darmerkrankungen
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5229374A (en) 1992-01-28 1993-07-20 Burton Albert F Method for treatment of lower gastrointestinal tract disorders
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5656283A (en) 1995-06-08 1997-08-12 Ortho Pharmaceutical Corporation In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product
WO1997009886A1 (en) 1995-09-15 1997-03-20 Gerding Dale N Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
US6103268A (en) 1995-11-03 2000-08-15 Borody; Thomas Julius Administering osmotic colonic evacuant containing a picosulfate
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
US5925354A (en) 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5711446A (en) 1996-01-16 1998-01-27 Sorenson Bioscience, Inc. Cryogenic freezing vial
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7430478B2 (en) 2000-03-01 2008-09-30 Caridian Bct, Inc. Blood processing information system with blood loss equivalency tracking
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
JP2003535903A (ja) 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2002220029B2 (en) 2000-11-14 2007-09-06 Techlab, Inc. Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
ES2329986T3 (es) 2001-09-06 2009-12-03 Rapid Micro Biosystems Inc Deteccion rapida de celulas en replicacion.
EP1300472A1 (en) 2001-10-02 2003-04-09 Stichting Top-Instituut Voedselwetenschappen A method for testing the effect of nutrients on gastrointestinal colonisation resistance of humans
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
US20030154105A1 (en) 2001-12-10 2003-08-14 Ferguson Martin L. Systems and methods for obtaining data correlated patient samples
US20030161871A1 (en) 2001-12-19 2003-08-28 Geoffrey Hird Solubilized riboflavin
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
ATE513551T1 (de) 2003-01-24 2011-07-15 Flora Technology Inc Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20060008511A1 (en) 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
US7935334B2 (en) 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
CA2582137A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
MX2007005491A (es) 2004-11-08 2007-09-27 Univ Yale Diseno de compuesto basado en la estructura que involucra riboconmutadores.
US20060210448A1 (en) 2005-03-10 2006-09-21 Naishu Wang Fecal specimen collection, preserving and transport device and method
US7607776B1 (en) 2005-10-24 2009-10-27 James Waller Lambuth Lewis Digital eye bank for virtual clinic trials
JP2009524411A (ja) 2005-12-21 2009-07-02 イェール ユニバーシティー リボスイッチの調節に関連した方法および組成物
AU2006330421B2 (en) 2005-12-29 2011-03-24 Hill's Pet Nutrition, Inc. Method for modifying gut flora in animals
US20080027353A1 (en) 2006-07-31 2008-01-31 Kliman Harvey J Method of making and using a library of biological information
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009055362A1 (en) 2007-10-26 2009-04-30 Moore Brenda E Probiotic compositions and methods for inducing and supporting weight loss
US20090148540A1 (en) 2007-12-10 2009-06-11 Mi Hope Incorporated Antibacterial composition and method of production
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
WO2009120347A2 (en) 2008-03-27 2009-10-01 Memorial Sloan Kettering Cancer Center Modulators of rna riboswitches
EP2310532B1 (en) 2008-06-30 2014-05-07 The Washington University Methods of promoting weight loss and associated arrays
US20100008850A1 (en) 2008-07-14 2010-01-14 William John Martin Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container
EP2320742B1 (en) 2008-07-17 2016-12-21 Bioworks, Inc. Control of plant diseases using a combination of a trichoderma virens species and a rhizosphere competent trichoderma harzianum species
AU2009282478A1 (en) 2008-08-11 2010-02-18 Biorelix,Inc. Flavin derivatives
EP2243487A1 (en) * 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
WO2011036539A1 (en) 2009-09-23 2011-03-31 Borody Thomas J Therapy for enteric infections
GB2487166B (en) 2009-10-22 2018-07-25 Borody Thomas J Composition comprising a fluoroquinolone and an imidazole for use in the treatment of Blastocystis hominis infection
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
NZ602473A (en) 2010-03-01 2015-01-30 Agronomique Inst Nat Rech Method of diagnostic of obesity
NZ602704A (en) 2010-03-01 2015-01-30 Agronomique Inst Nat Rech Method of diagnostic of inflammatory bowel diseases
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
FI20105825A (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012033814A2 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
WO2012050513A1 (en) 2010-10-11 2012-04-19 Baeckhed Fredrik Method for identifying a risk of cardiovascular disease by analysing oral microbiota
EP2680866A1 (en) 2011-03-01 2014-01-08 Quorum Innovations, LLC Materials and methods for treating conditions associated with pathogenic biofilm
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276060A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
US20140179726A1 (en) 2011-05-19 2014-06-26 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN104024430A (zh) 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
WO2013037068A1 (en) 2011-09-14 2013-03-21 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
LT2750682T (lt) 2011-10-11 2016-10-10 Achim Biotherapeutics Ab Kompozicija, apimanti anaerobiškai auginamą žmogaus žarnyno mikroflorą
EP2776016B1 (en) 2011-11-09 2019-02-20 Capsugel Belgium NV Acid resistant banding solution for acid resistant two piece hard capsules
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
US9421233B2 (en) 2012-04-27 2016-08-23 Cedars-Sinai Medical Center Fungal mycobiome as probiotics, diagnostics and therapeutics
DK2850202T3 (da) 2012-05-18 2020-05-18 Genome Res Ltd Fremgangsmåder og grupper
EP2866836A1 (en) 2012-07-02 2015-05-06 DSM IP Assets B.V. Capsules containing thymoquinone
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP6506173B2 (ja) 2012-11-23 2019-04-24 セレス セラピューティクス インコーポレイテッド 相乗的細菌組成物並びにその生成及び使用の方法
EP2922555A4 (en) 2012-11-26 2016-06-15 Borody Thomas J COMPOSITIONS FOR THE RESTORATION OF AN FECAL MICROBIOTE AND METHODS OF MAKING AND USING THEM
NZ708533A (en) * 2012-11-29 2019-11-29 Progel Pty Ltd Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
BR112015018625A2 (pt) * 2013-02-04 2017-09-19 Seres Therapeutics Inc composições e métodos
US9192361B2 (en) 2013-02-26 2015-11-24 Christopher J Stevens Fecal microbiome transplant material preparation method and apparatus
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511100B2 (en) * 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20150037285A1 (en) 2013-07-03 2015-02-05 New York University Methods for efficient transfer of viable and bioactive microbiota
EP3035944B1 (en) 2013-08-22 2019-10-02 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Probiotics for use in the treatment of bacterial vaginosis
JP2015091647A (ja) * 2013-09-30 2015-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 マーキング方法、レーザー転写フィルム、インク組成物、マークが施された転写対象可食物及びその製造方法
CN104922158B (zh) * 2015-06-05 2018-11-02 中国人民解放军第三军医大学第三附属医院 粪菌胶囊及其制备与应用
CN105103858A (zh) 2015-08-17 2015-12-02 太仓市雅丰农场专业合作社 一种小麦的种植方法
CN105193858A (zh) * 2015-09-25 2015-12-30 南昌大学 一种天然粪便菌群移植在肠道疾病治疗中的应用

Also Published As

Publication number Publication date
EP3939601A1 (en) 2022-01-19
KR102342925B1 (ko) 2021-12-23
KR102066242B1 (ko) 2020-01-14
HK1254281A1 (zh) 2019-07-19
AU2020220084A1 (en) 2020-09-03
BR112017026586B1 (pt) 2021-11-03
KR20200127060A (ko) 2020-11-09
JP2020037573A (ja) 2020-03-12
US10391064B2 (en) 2019-08-27
US20160361263A1 (en) 2016-12-15
KR20180016539A (ko) 2018-02-14
AU2019203164A1 (en) 2019-05-30
AU2020220084B2 (en) 2022-07-21
US20170252303A1 (en) 2017-09-07
IL281424B1 (en) 2023-06-01
IL256033A (en) 2018-01-31
IL281424B2 (en) 2023-10-01
IL281424A (en) 2021-04-29
JP6616431B2 (ja) 2019-12-04
US10226431B2 (en) 2019-03-12
AU2016274757A1 (en) 2018-01-04
IL256033B (en) 2021-03-25
WO2016201114A1 (en) 2016-12-15
EP3307289B1 (en) 2021-08-04
AU2022256174A1 (en) 2022-11-24
AU2019203164B2 (en) 2020-05-21
EP3307289A1 (en) 2018-04-18
KR20200006181A (ko) 2020-01-17
JP2018516960A (ja) 2018-06-28
BR112017026586A2 (pt) 2018-08-14
AU2016274757B2 (en) 2019-02-07
CN107921072A (zh) 2018-04-17
CA2986915C (en) 2023-09-19
JP6907288B2 (ja) 2021-07-21
ES2889902T3 (es) 2022-01-14
CA2986915A1 (en) 2016-12-15
KR102175829B1 (ko) 2020-11-06

Similar Documents

Publication Publication Date Title
IL281424A (en) Microbiota restoration treatment preparations and production methods
IL263175B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
EP3386484A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING THERAPEUTIC AGENTS
IL254016A0 (en) A preparation for medical and preventive treatment produced by microbiota
HK1258062A1 (zh) 給予惡拉戈利的方法
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3341392A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
EP3253211A4 (en) Compositions and methods for treatment of edema
EP3307081A4 (en) LECITHIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE OF SUCH LECITHIN COMPOSITIONS
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HOMOCYSTINURIA
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
EP3325019A4 (en) COMPOSITES AND COMPOSITIONS FOR USE IN THERAPEUTIC PURPOSE AND METHODS OF MAKING AND USING SAME
EP3151862A4 (en) Therapeutic detoxification compositions and methods of making and using same
HK1248527A1 (zh) 牙科組合物和使用方法
EP3362085A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING MUCIN
EP3294417A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOMES
EP3344593A4 (en) COMPOSITIONS AND METHOD FOR BOREOLE CEMENTING
GB201614997D0 (en) Oligosaccharide compositions and methods of making and using them
AU2015903210A0 (en) Compositions and methods of treatment